Targeted Oncology43m
FDA Fast Tracks Amezalpat for HCC Treatment
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Science Daily3h
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Cancer Therapy Advisor12h
Amezalpat Gets Fast Track Designation for HCC
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
Frontiers4d
Using Oncolytic Viruses in Cancer Immunity and Immunotherapy: Hepatocellular Carcinoma, Gastric Cancer, and Colorectal Cancer
Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...
Frontiers8d
Novel Therapeutic Approaches for Biliary Tract Cancer and Hepatocellular Carcinoma, Volume II
Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...
European Medical Journal7d
New Model Predicts Hepatocellular Carcinoma Risk in Patients with Noncirrhotic Hepatitis B
New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.